Gentium says Defibrotide may prevent endothelial complications

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Gentium SpA said it will make an oral presentation entitled, "Defibrotide Modulates Immune Functions of Endothelial Cells - Impact for Transplantation and Cancer Therapy," at the 16th European Congress of Immunology this week in Paris.

The presentation will show evidence that Defibrotide can protect endothelial cells from conditioning-mediated cell death, which suggests that the drug may be used as a prophylactic in patients at risk for complications of the endothelial cells, which line blood and lymph vessels.

The company said this evidence demonstrates that Defibrotide has anti-inflammatory activity because it prevents transendothelial migration of immune effector cells and that it can reduce the chemotherapy-induced antigenicity of endothelial cells towards allogeneic cytotoxic T lymphocytes.

The data further suggests that in addition to its endothelium-protecting function, Defibrotide can also inhibit blood vessel formation, the Como, Italy-based pharmaceutical company noted.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.